Mitsubishi Tanabe Pharma America announced that more than 10,000 people with amyotrophic lateral sclerosis (ALS) have received treatment with intravenous (IV) RADICAVA® (edaravone) and/or RADICAVA ORS® (edaravone) since the therapies became available in the U.S. in August 2017 and June 2022, respectively. To date, more than 2,000 U.S. HCPs have prescribed RADICAVA ORS and/or RADICAVA to one or more of their patients, and 79% of people who started treatment in the six-month period between June 1, 2022 and November 30, 2022 have continued treatment for three months or more through February.2,3 RADICAVA ORS and RADICAVA are widely distributed by specialty pharmacies across the U.S. and in Puerto Rico.
"This product milestone falls on MTPA's seventh anniversary as a U.S. company committed to helping those with ALS," said Atsushi Fujimoto, President, MTPA. "Addressing the unmet needs of people living with serious, debilitating diseases like ALS, is of the utmost importance to us, and we remain focused on delivering meaningful treatments to this community."
RADICAVA ORS is an oral formulation that offers the same efficacy as RADICAVA and was shown in a pivotal trial to help slow the loss of physical function in ALS.4,5 To learn more about RADICAVA ORS, including information about dosing and administration, visit RADICAVA.com.
"As one of the first physicians to prescribe RADICAVA IV in 2017 and the oral formulation in 2022, this milestone holds significant meaning for me," said Benjamin Rix Brooks, M.D., ALS specialist. "ALS is a devastating disease with no cure, but it's reassuring to know that many living with the disease have received therapy with a treatment that may slow their disease progression."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!